Caris Life Sciences, Inc. CAI
25.71 USD +0.48 (+1.90%)
Nov 9, 2026, 3:06 PM EST
24.60 Day range 25.72
14.19 52-week range 36.50
- YTD
- -4.71%
- 1 year
- +0.39%
News
benzinga.com Citigroup Maintains Buy on Caris Life Sciences, Raises Price Target to $36 Citigroup analyst Albert Hu maintains Caris Life Sciences (NASDAQ:CAI) with a Buy and raises the price target from $28 to $36.
benzinga.com TD Cowen Maintains Buy on Caris Life Sciences, Raises Price Target to $38 TD Cowen analyst Dan Brennan maintains Caris Life Sciences (NASDAQ:CAI) with a Buy and raises the price target from $36 to $38.
benzinga.com VIX Spikes 39% as AI Tech Rout Wipes Out $2.2 Trillion: Stock Market Today The AI sell-off deepens after the Democratic midterm sweep, sending the S&P 500 toward its worst day since April 2025 as Nvidia, AMD and Micron sank.
benzinga.com Zillow Posts Downbeat Q3 Results, Joins HubSpot, Snap And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session U.S. stock futures were mixed as Zillow and several companies fell sharply premarket after weak results and lowered sales guidance.
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session Gainers ADMA Biologics (NASDAQ:ADMA) shares rose 19.6% to $12.53 during Thursday's pre-market session. The market value of their outstanding shares is at $2.3 billion. As per the news, the Q3…
seekingalpha.com Caris Life Sciences, Inc. (CAI) Q3 2026 Earnings Call Transcript Caris Life Sciences, Inc. (CAI) Q3 2026 Earnings Call Transcript
marketbeat.com Caris Life Sciences Q3 Earnings Call Highlights Caris Life Sciences NASDAQ: CAI raised its full-year revenue outlook after third-quarter sales rose 27%, as growth in cancer-testing volumes accelerated for a second consecutive quarter. The company…
zacks.com Caris Life Sciences,?Inc. (CAI) Q3 Earnings and Revenues Top Estimates Caris Life Sciences,?Inc. (CAI) came out with quarterly earnings of $0.05 per share, beating the Zacks Consensus Estimate of $0.03 per share. This compares to earnings of $0.08 per share a year ago.
benzinga.com Caris Life Sciences Q3 2026 Earnings Call Transcript Caris Life Sciences (NASDAQ:CAI) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.Benzinga APIs provide…
benzinga.com Caris Life Sciences Raises FY2026 Sales Guidance from $1.030B-$1.040B to $1.040B-$1.050B vs $1.030B Est Caris Life Sciences (NASDAQ:CAI) raises FY2026 sales outlook from $1.030 billion-$1.040 billion to $1.040 billion-$1.050 billion vs $1.030 billion estimate.
benzinga.com Caris Life Sciences Q3 EPS $0.05 Beats $0.04 Estimate, Sales $275.358M Beat $255.363M Estimate Caris Life Sciences (NASDAQ:CAI) reported quarterly earnings of $0.05 per share which beat the analyst consensus estimate of $0.04 by 25 percent. This is a 37.5 percent decrease over earnings of…
prnewswire.com Caris Life Sciences Reports Third Quarter 2026 Financial Results and Increases 2026 Revenue Guidance Revenue growth of 27% driven by strong performance in molecular profiling services, including approximately 61,500 clinical cases, consisting of over 358,000 total oncology tests Raises 2026 revenue…
benzinga.com BTIG Maintains Buy on Caris Life Sciences, Raises Price Target to $38 BTIG analyst Mark Massaro maintains Caris Life Sciences (NASDAQ:CAI) with a Buy and raises the price target from $33 to $38.
benzinga.com Canaccord Genuity Maintains Hold on Caris Life Sciences, Raises Price Target to $30 Canaccord Genuity analyst Kyle Mikson maintains Caris Life Sciences (NASDAQ:CAI) with a Hold and raises the price target from $22 to $30.
benzinga.com Truist Financial, Regions Financial And Other Big Stocks Moving Lower In Friday’s Pre-Market Session U.S. stock futures mixed; Truist slips after mixed results, while Telkom Indonesia, Loma Negra, Omeros and others fall premarket.
benzinga.com Nasdaq 100 Drops 1% on Hot CPI, SOXX Falls 7th Day: Stock Market Today The Nasdaq 100 fell 1% by midday Wednesday after September CPI topped forecasts, pushing Treasury yields and rate-hike bets higher.- benzinga.com TD Cowen Maintains Buy on Caris Life Sciences, Raises Price Target to $36 TD Cowen analyst Dan Brennan maintains Caris Life Sciences (NASDAQ:CAI) with a Buy and raises the price target from $30 to $36.
benzinga.com S&P 500, Nasdaq Hit Records, Power Stocks Rally on Google's Nuclear Deal: Stock Market Today S&P 500 and Nasdaq 100 hit records as the 10-year yield retreats from a 24-year high; Constellation Energy jumps on a Google nuclear deal.
benzinga.com 10-Year Yield Tops 5%, Oil Storms Past $105: Stock Market Today The 10-year Treasury yield broke 5% for the first time since 2007 as WTI surged past $105 on Saudi pipeline outages, pressuring stocks ahead of the Fed.
benzinga.com Caris Life Sciences Announces Publication Of Study Validating An AI-Driven Approach To First-Line Treatment Selection In Pancreatic Cancer In The Journal 'npj Precision Oncology' The study demonstrates the performance of Caris AI Insights™ to predict first-line treatment benefit using an AI–based molecular signature. In the testing cohort, standard molecular risk patients…
benzinga.com Nasdaq 100 Falls as Hot PCE Inflation Stirs Rate-Hike Bets: Stock Market Today Nasdaq 100 falls 0.6% as traders wait on Nvidia and hot July PCE revives September rate-hike bets. Energy leads, gold sinks 1.3% to $4,599.
benzinga.com Bessent's Bond Rescue Fizzles, Walmart Craters 9%: Stock Market Today Long-end Treasury yields snapped back toward 20-month highs; Walmart posted its worst session in four years.
benzinga.com Deere, Coinbase Global, Nordson And Other Big Stocks Moving Higher On Wednesday Dow Jones down 300 points, Deere & Co shares up 7.9% after beating earnings expectations. SCTX, SCSC, BTBT, MRVI, HIVE, AHG, TEM, MARA, LB also gain.- benzinga.com Evercore ISI Group Maintains Outperform on Caris Life Sciences, Raises Price Target to $26 Evercore ISI Group analyst Vijay Kumar maintains Caris Life Sciences (NASDAQ:CAI) with a Outperform and raises the price target from $25 to $26.
- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session Gainers Creative Medical Tech (NASDAQ:CELZ) stock moved upwards by 31.4% to $0.88 during Wednesday's after-market session. The company's market cap stands at $4.2 million. Caris Life Sciences…
- benzinga.com Caris Life Sciences Raises FY2026 Sales Guidance from $1.000B-$1.020B to $1.030B-$1.040B vs $1.003B Est Caris Life Sciences (NASDAQ:CAI) raises FY2026 sales outlook from $1.000 billion-$1.020 billion to $1.030 billion-$1.040 billion vs $1.003 billion estimate.
benzinga.com Caris Life Sciences To Offer In-House PTEN Immunohistochemistry Testing After Recent FDA Approval Of Biomarker-Guided Therapy And Diagnostic Assay This testing is designed to help identify patients with PTEN-deficient metastatic androgen pathway modulation-naïve or -sensitive (mAPMN/S) prostate cancer (previously known as metastatic…
benzinga.com Caris Life Sciences Announces Dual Listing Of Common Shares On NYSE Texas, Effective June 17 Caris Life Sciences® (NASDAQ: CAI), a leading patient-centric next-generation AI TechBio company and precision medicine pioneer, today announced the dual listing of its common stock on NYSE Texas…- benzinga.com Caris Life Sciences Announces $100M Buyback Plan Caris Life Sciences® (Nasdaq: CAI) ("Caris" or the "Company"), a leading next-generation AI TechBio company and precision medicine pioneer, today announced that its Board of Directors has authorized…
benzinga.com Stock Market Today: Nasdaq 100 Slips As Broadcom Plunges, Bitcoin Hits 4-Month Lows A selloff in high-flying chipmakers split Wall Street on Thursday, with Broadcom Inc. (NASDAQ:AVGO)‘s disappointing AI-revenue forecast testing the artificial-intelli
benzinga.com Stanley Druckenmiller Dumps Amazon And Alphabet While Loading Up On Commodities, Argentina And Biotech Stanley Druckenmiller cut Amazon, exited Alphabet while increasing bets on Argentina, commodities, semiconductors, biotech stocks during Q1.- benzinga.com Caris Life Sciences Announces Publication Of A Caris‑Led Study In The Oncologist The Shows Its Lookback Program's Ability To Identify Previously-Profiled Patients Who Become Eligible For Newly Approved Targeted Therapies Molecular profiling reports from most labs are static, reflecting clinical knowledge only at the time of testing. As new biomarker–drug associations and therapeutic indications emerge, patients with…
- benzinga.com Citigroup Maintains Buy on Caris Life Sciences, Lowers Price Target to $28 Citigroup analyst Patrick Donnelly maintains Caris Life Sciences (NASDAQ:CAI) with a Buy and lowers the price target from $35 to $28.
- benzinga.com Caris Life Sciences Submits Application To NYSDOH Clinical Laboratory Evaluation Program Seeking Authorization To Perform Caris Assure On Specimens Originating From New York State Caris Life Sciences® (NASDAQ:CAI), a leading patient-centric next-generation AI TechBio company and precision medicine pioneer, today announced that it has submitted an application to the New York…
- benzinga.com JP Morgan Maintains Overweight on Caris Life Sciences, Lowers Price Target to $30 JP Morgan analyst Casey Woodring maintains Caris Life Sciences (NASDAQ:CAI) with a Overweight and lowers the price target from $35 to $30.
- benzinga.com BTIG Maintains Buy on Caris Life Sciences, Lowers Price Target to $32 BTIG analyst Mark Massaro maintains Caris Life Sciences (NASDAQ:CAI) with a Buy and lowers the price target from $38 to $32.
benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session - benzinga.com Caris Life Sciences Affirms FY2026 Sales Guidance of $1.000B-$1.020B vs $1.007B Est Caris Life Sciences (NASDAQ:CAI) affirms FY2026 sales outlook from $1.000 billion-$1.020 billion to $1.000 billion-$1.020 billion vs $1.007 billion estimate.
- benzinga.com Caris Life Sciences Q1 Sales $216.174M Beat $210.292M Estimate Caris Life Sciences (NASDAQ:CAI) reported quarterly sales of $216.174 million which beat the analyst consensus estimate of $210.292 million by 2.80 percent. This is a 78.78 percent increase over…
- benzinga.com Caris Life Receives MolDX Approval For Caris ChromoSeq Caris Life Sciences® (NASDAQ:CAI), a leading, patient‑centric, next‑generation AI TechBio company and precision medicine pioneer, today announced that Caris ChromoSeq™ has received MolDX approval, a…
benzinga.com Leggett & Platt, Allogene Therapeutics, Revolution Medicines And Other Big Stocks Moving Higher On Monday U.S. stocks were mixed on Monday, with the Dow Jones falling over 200 points. Leggett & Platt rose on news of being acquired by Somnigroup.- benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session
benzinga.com Why Applied Optoelectronics Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket 
benzinga.com Earnings Scheduled For February 26, 2026 
benzinga.com Russell 2000 Drop, EM Stocks Hit Records After Court's Tariff Ruling: What's Moving Markets Friday? Small caps lagged while emerging markets surged to record highs amid historic Supreme Court's ruling against Trump's tariffs.
benzinga.com This AeroVironment Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday 
benzinga.com Gold, Silver Spike To Record Highs As Fed Independence Falters: What's Moving Markets Monday? Gold and silver surged to fresh record highs Monday as investors reassessed the Federal Reserve's independence fears amid a new political escalation.- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
benzinga.com Earnings Scheduled For November 5, 2025 - benzinga.com Stocks That Hit 52-Week Highs On Wednesday During Wednesday's morning trading, 472 companies set new 52-week highs.